Written answers

Wednesday, 24 November 2021

Department of Health

Cannabis for Medicinal Use

Photo of Róisín ShortallRóisín Shortall (Dublin North West, Social Democrats)
Link to this: Individually | In context | Oireachtas source

204. To ask the Minister for Health the status of the proposed legislative amendment which will allow cannabis based-products available in the UK to be considered for inclusion on the Medical Cannabis Access Programme (details supplied); when he expects this legislation to be implemented; and if he will make a statement on the matter. [57842/21]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

Under the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (S.I. 262/2019) in the definition “specified controlled drugs” the cannabis product or prepararion must be one:

(d) which is permitted to be sold or supplied for medical purposes by the relevant public or state body of a Member State other than the State,

(e) which is currently supplied to patients in the Member State referred to in sub-paragraph (d),

(f) which is packaged and labelled in the English language and in accordance with guidance on labelling and packaging as published by the Authority, and

(g) which is specified in Schedule 1;

Member state is defined as "a state which is a contracting party to the Agreement on the European Economic Area signed in Oporto on 2 May 1992, as adjusted by the Protocol to that Agreement done at Brussels on 17 March 1993"

The United Kingdom is not included in the definition as it is no longer a Member State.

The proposed legislative amendment referred to is the subject of ongoing discussions between officials in the Department of Health and the Health Products Regulatory Authority.


No comments

Log in or join to post a public comment.